Per-6-Thiolated Cyclodextrins: A Novel Type of Permeation Enhancing Excipients for BCS Class IV Drugs.
Animals
Biological Availability
Caco-2 Cells
Chromatography, High Pressure Liquid
Cyclodextrins
/ chemistry
Excipients
/ chemistry
Furosemide
/ analogs & derivatives
Humans
Intestinal Mucosa
/ drug effects
Magnetic Resonance Spectroscopy
Mucus
/ drug effects
Pharmaceutical Preparations
/ metabolism
Rats
Rats, Sprague-Dawley
Rheology
Solubility
Spectroscopy, Fourier Transform Infrared
Sulfhydryl Compounds
/ chemistry
Swine
Viscosity
BCS Class IV drugs
mucoadhesion
per-6-thiolated cyclodextrin
permeation enhancement
solubility improvement
thiolated
thiolated cyclodextrin
thiomers
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
19 Feb 2020
19 Feb 2020
Historique:
pubmed:
28
1
2020
medline:
15
12
2020
entrez:
28
1
2020
Statut:
ppublish
Résumé
The purpose of the study was to develop a per-6-thiolated α-cyclodextrin (α-CD) by substituting all primary hydroxyl groups of α-CD with thiol groups and to assess its solubility-improving and permeation-enhancing properties for a BCS Class IV drug in vitro as well as in vivo. The primary hydroxyl groups of α-CD were replaced by iodine, followed by substitution with -SH groups. The structure of per-6-thiolated α-CD was approved by FT-IR and
Identifiants
pubmed: 31985207
doi: 10.1021/acsami.9b21335
pmc: PMC7205388
doi:
Substances chimiques
Cyclodextrins
0
Excipients
0
Pharmaceutical Preparations
0
Sulfhydryl Compounds
0
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7942-7950Références
PLoS One. 2014 Jul 03;9(7):e101414
pubmed: 24992195
J Pharm Pharm Sci. 2000 May-Aug;3(2):220-7
pubmed: 10994035
J Pharm Pharmacol. 1994 Feb;46(2):86-90
pubmed: 8021811
Eur J Pharm Biopharm. 2018 Dec;133:188-199
pubmed: 30359716
J Pharm Sci. 2016 Sep;105(9):2848-2854
pubmed: 27233687
J Biomater Appl. 2003 Jan;17(3):197-206
pubmed: 12614084
J Pharm Pharmacol. 1998 Feb;50(2):159-66
pubmed: 9530983
J Control Release. 2013 Feb 10;165(3):207-15
pubmed: 23228848
Arch Pharm Res. 2011 Nov;34(11):1989-97
pubmed: 22139699
Saudi Pharm J. 2019 Jan;27(1):96-105
pubmed: 30662312
Eur J Pharm Biopharm. 2017 Oct;119:161-169
pubmed: 28610879
Chem Rev. 1998 Jul 30;98(5):1977-1996
pubmed: 11848955
Biomacromolecules. 2002 Nov-Dec;3(6):1304-11
pubmed: 12425669
Pharm Res. 2002 May;19(5):602-8
pubmed: 12069161
J Mater Sci Mater Med. 2013 Jun;24(6):1375-82
pubmed: 23468164
J Control Release. 1999 May 1;59(1):107-18
pubmed: 10210727
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1569-82
pubmed: 16176846
Int J Pharm. 2015 Dec 30;496(2):304-13
pubmed: 26453783
Pharmaceutics. 2019 Nov 29;11(12):
pubmed: 31795506
Int J Pharm. 2012 Nov 15;438(1-2):217-24
pubmed: 22960503
Int J Biol Macromol. 2019 Jun 1;130:148-157
pubmed: 30779984
Eur J Pharm Biopharm. 2016 Mar;100:9-14
pubmed: 26692501
J Cell Sci. 1995 Feb;108 ( Pt 2):609-19
pubmed: 7769005
Int J Nanomedicine. 2018 Jul 10;13:4003-4013
pubmed: 30022823
Int J Pharm. 2017 Dec 20;534(1-2):339-347
pubmed: 29111098
Future Microbiol. 2019 Mar;14:411-424
pubmed: 30854897
Int J Pharm. 2003 Jul 24;260(2):229-37
pubmed: 12842342
Eur J Cell Biol. 1998 Jun;76(2):85-92
pubmed: 9696347
Expert Opin Drug Deliv. 2011 Jun;8(6):721-34
pubmed: 21463219
J Colloid Interface Sci. 2018 Dec 1;531:261-268
pubmed: 30036850
Int J Pharm. 2017 Jun 30;526(1-2):366-379
pubmed: 28487189
Int J Pharm. 2016 Jan 30;497(1-2):123-8
pubmed: 26631639
Pharm Res. 1996 Sep;13(9):1336-42
pubmed: 8893271
PLoS One. 2013 Nov 18;8(11):e79954
pubmed: 24260326
Nat Protoc. 2007;2(9):2111-9
pubmed: 17853866